Payment overview · 2025
General Payments
$721.94
33 reported records · 16 companies
Healthcare provider profile · identity verified
Joseph E Goin, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLEVELAND, TX · NPI 1730189408
Verified facts
What the public records show
CMS Open Payments records show Joseph E Goin, MD received $721.94 in general payments during 2025 across 33 reported records.
Inspire Medical Systems, Inc. accounted for 15.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $111.44 | 15.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $106.74 | 14.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $84.91 | 11.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.17 | 9.4% | 3 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $52.83 | 7.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.12 | 6.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.51 | 6.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.07 | 5.4% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $31.44 | 4.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.75 | 4.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.61 | 3.8% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $24.06 | 3.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.89 | 2.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.43 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.98 | 1.9% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $2.99 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $721.94 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $111.44 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $106.74 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.66 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.64 | 2 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $52.83 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.12 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.51 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.51 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.51 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.07 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $2.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 42 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
46 | 44 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 637 | 240 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 145 |
| Losartan Potassium | Losartan Potassium | 357 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 139 |
| Gabapentin | Gabapentin | 313 | 112 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 303 | 110 |
| Metformin Hcl | Metformin Hcl | 248 | 96 |
| Lisinopril | Lisinopril | 246 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 104 |
| Furosemide | Furosemide | 180 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 62 |
| Omeprazole | Omeprazole | 147 | 63 |
| Clonazepam | Clonazepam | 143 | 32 |
| Carvedilol | Carvedilol | 137 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 42 |
| Tramadol Hcl | Tramadol Hcl | 130 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 48 |
| Ezetimibe | Ezetimibe | 126 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 49 |
| Alprazolam | Alprazolam | 119 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 39 |
| Simvastatin | Simvastatin | 110 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 45 |
| Pregabalin | Pregabalin | 104 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 102 | 18 |
| Trazodone Hcl | Trazodone Hcl | 98 | 37 |
| Jardiance | Empagliflozin | 97 | 25 |
| Meloxicam | Meloxicam | 97 | 33 |
| Mounjaro | Tirzepatide | 96 | 25 |
| Ozempic | Semaglutide | 92 | 27 |
| Potassium Chloride | Potassium Chloride | 92 | 37 |
| Glimepiride | Glimepiride | 91 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 31 |
| Prednisone | Prednisone | 79 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 23 |
| Montelukast Sodium | Montelukast Sodium | 77 | 35 |
| Lorazepam | Lorazepam | 76 | 15 |
| Eliquis | Apixaban | 75 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 25 |
| Famotidine | Famotidine | 69 | 26 |
| Sertraline Hcl | Sertraline Hcl | 69 | 28 |
| Clonidine Hcl | Clonidine Hcl | 66 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 25 |
| Atenolol | Atenolol | 61 | 21 |
| Mirtazapine | Mirtazapine | 61 | 22 |
| Alendronate Sodium | Alendronate Sodium | 57 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 18 |
| Farxiga | Dapagliflozin Propanediol | 54 | 20 |
| Metformin Hcl Er | Metformin Hcl | 54 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 26 |
| Ibuprofen | Ibuprofen | 52 | 23 |
| Trulicity | Dulaglutide | 52 | 18 |
| Nifedipine Er | Nifedipine | 51 | 23 |
| Glipizide | Glipizide | 50 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 18 |
| Fenofibrate | Fenofibrate | 49 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 44 |
| Azithromycin | Azithromycin | 44 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 16 |
| Cephalexin | Cephalexin | 43 | 36 |
| Buspirone Hcl | Buspirone Hcl | 42 | 23 |
| Gemtesa | Vibegron | 42 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 42 | 14 |
| Finasteride | Finasteride | 41 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 24 |
| Naproxen | Naproxen | 40 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 16 |
| Aripiprazole | Aripiprazole | 39 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 17 |
| Bupropion Xl | Bupropion Hcl | 38 | 16 |
| Allopurinol | Allopurinol | 37 | 16 |
| Valsartan | Valsartan | 37 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 16 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Cefdinir | Cefdinir | 29 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 13 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | 12 |
| Meclizine Hcl | Meclizine Hcl | 26 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Baclofen | Baclofen | 23 | 11 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Diazepam | Diazepam | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Epinephrine | Epinephrine | 20 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Risperidone | Risperidone | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Constulose | Lactulose | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Nystatin | Nystatin | 15 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Rinvoq | Upadacitinib | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $721.94 · 33 records | Inspire Medical Systems, Inc. | ABRYSVO, AIRSUPRA, Azstarys, BEYFORTUS, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, Flexitouch Plus, GEMTESA, INGREZZA, INSPIRE, MENQUADFI, NEFFY, Nimbl, Onyda XR, PREVNAR 20, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Veozah, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error